Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-chloro-n(6)-(3-iodobenzyl)-9-(5-(methylcarbamoyl)-beta-d-ribofuranosyl)adenine
2. 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
3. 2-chloro-n6-(3-iodobenzyl)adenosine-5'-n-methylcarboxamide
4. 2-cl-ib-meca
5. C-ibza-mu
6. Cf102 Compound
1. 2-cl-ib-meca
2. 163042-96-4
3. Namodenoson
4. Cl-ib-meca
5. Cf-102
6. Cf102
7. C-ibza-mu
8. (2s,3s,4r,5r)-5-(2-chloro-6-((3-iodobenzyl)amino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyltetrahydrofuran-2-carboxamide
9. Ci-ib-meca
10. 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
11. Namodenoson [usan]
12. 2cl-ib-meca
13. (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide
14. Chembl431733
15. Z07jr07j6c
16. 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-1-deoxy-n-methyl-beta-d-ribofuranuronamide
17. Unii-z07jr07j6c
18. 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-1-deoxy-n-methyl-beta-d-ribofuranuronamide
19. Beta-d-ribofuranuronamide, 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-1-deoxy-n-methyl-
20. Beta-d-ribofuranuronamide, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-1-deoxy-n-methyl-
21. Cf 102
22. 2-chloro-n6-(3-iodobenzyl)adenosine-5'-n-methylcarboxamide
23. Namodenoson [inn]
24. Namodenoson (cf-102)
25. Namodenoson (usan/inn)
26. C1-ib-meca
27. 2-chloro-n(6)-(3-iodobenzyl)-9-(5-(methylcarbamoyl)-beta-d-ribofuranosyl)adenine
28. Gtpl457
29. Namodenoson [who-dd]
30. Mls002153535
31. Schembl1170028
32. Bdbm21221
33. 2-chloro-n6-(3-iodobenzyl)adenosine-5'-n-methyluronamide
34. Cf-102;2-cl-ib-meca
35. Dtxsid80167504
36. Hms2235l10
37. Hms3412i05
38. Hms3676i05
39. Cf-102(2-cl-ib-meca)
40. Ex-a2882
41. Zinc3995845
42. Mfcd01861178
43. Akos022181265
44. Am84557
45. Cs-5932
46. Db12885
47. Ncgc00025001-02
48. Ac-27390
49. Ds-16397
50. Hy-12365
51. Smr001230862
52. Chloro-ib-meca, Solid, >=98% (hplc)
53. B6597
54. C3601
55. S0498
56. D11128
57. P10208
58. A848899
59. J-009992
60. Q27076097
61. 2-chloro-n6-(3-iodobenzyl)adenosine-5-n-methylcarboxamide
62. (2s,3s,4r,5r)-5-(2-chloro-6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyltetrahydrofuran-2-carboxamide
63. (2s,3s,4r,5r)-5-(2-chloro-6-{[(3-iodophenyl)methyl]amino}-9h-purin-9-yl)-3,4-dihydroxy-n-methyloxolane-2-carboxamide
64. (2s,3s,4r,5r)-5-(6-(3-iodobenzylamino)-2-chloro-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide
65. .beta.-d-ribofuranuronamide, 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-1-deoxy-n-methyl-
66. 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-1-deoxy-n-methyl-.beta.-d-ribofuranuronamide
67. 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-1-deoxy-n-methyl-?-d-ribofuranuronamide
68. 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-1-deoxy-n-methyl-beta-d-ribofuranuronamide;2-chloro-n6-(3-iodobenzyl)adenosine-5'-n-methyluronamide;2-cl-ib-meca;2-cl-ib-meca
| Molecular Weight | 544.7 g/mol |
|---|---|
| Molecular Formula | C18H18ClIN6O4 |
| XLogP3 | 1.9 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 544.01228 g/mol |
| Monoisotopic Mass | 544.01228 g/mol |
| Topological Polar Surface Area | 134 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 623 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Purinergic P1 Receptor Agonists
Compounds that bind to and stimulate PURINERGIC P1 RECEPTORS. (See all compounds classified as Purinergic P1 Receptor Agonists.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Namodenoson manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Namodenoson, including repackagers and relabelers. The FDA regulates Namodenoson manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Namodenoson API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Namodenoson supplier is an individual or a company that provides Namodenoson active pharmaceutical ingredient (API) or Namodenoson finished formulations upon request. The Namodenoson suppliers may include Namodenoson API manufacturers, exporters, distributors and traders.
Namodenoson Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Namodenoson GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Namodenoson GMP manufacturer or Namodenoson GMP API supplier for your needs.
A Namodenoson CoA (Certificate of Analysis) is a formal document that attests to Namodenoson's compliance with Namodenoson specifications and serves as a tool for batch-level quality control.
Namodenoson CoA mostly includes findings from lab analyses of a specific batch. For each Namodenoson CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Namodenoson may be tested according to a variety of international standards, such as European Pharmacopoeia (Namodenoson EP), Namodenoson JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Namodenoson USP).
LOOKING FOR A SUPPLIER?
